Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Ceribell receives FDA 510(k) clearance for delirium monitoring solution

by mariel | Dec 9, 2025 | Portfolio News

Ceribell reported > $22M Q3’25 revenue, raised FY25 revenue guidance to $87M–$89M, and received FDA 510(k) clearance for its delirium monitoring solution.

Mirum enters definitive agreement to acquire Bluejay Therapeutics

by mariel | Dec 8, 2025 | Portfolio News

Mirum announced a definitive agreement to acquire Bluejay and add worldwide rights to brelovitug; Mirum also completed private placements totaling $268M to finance the transaction.

Vera submits BLA for atacicept in IgA nephropathy; FDA assigns PDUFA date

by mariel | Nov 7, 2025 | Portfolio News

Vera submitted a BLA via Accelerated Approval for atacicept in IgAN and later reported a PDUFA target action date of July 7, 2026.

Roche completes acquisition of 89bio; Longitude funds report transaction closed Oct. 30

by mariel | Oct 30, 2025 | Portfolio News

Funds reported the Roche transaction closed October 30 and that 89bio will no longer be reported going forward.

Novartis completes acquisition of Tourmaline Bio

by mariel | Oct 28, 2025 | Portfolio News

Novartis completed its acquisition of Tourmaline Bio following the previously announced all-cash agreement at $48/share.

Boston Scientific to acquire Nalu Medical for $533M (cash)

by mariel | Oct 17, 2025 | Portfolio News

Nalu Medical agreed to be acquired by Boston Scientific for $533 million in cash (excluding Boston Scientific’s existing strategic investments).
« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer